10-Q · May 12, 2026
Hyliion's Q1 2026 results showed impressive revenue growth driven by increased R&D services, reaching $2.83 million, significantly surpassing the $1 million estimate. The company improved its EPS loss to $0.07 from a…
Earnings analysis · 10-Q
Filed August 11, 2026 · Our reading of the company's report
The latest report
Hyliion’s Q2 2026 revenue increased to $4.944 million from $2 million a year earlier, and full-year revenue guidance was raised to $15 million from approximately $10 million. However, diluted EPS remained negative at…
Hyliion’s Q2 2026 revenue increased to $4.944 million from $2 million a year earlier, and full-year revenue guidance was raised to $15 million from approximately $10 million. However, diluted EPS remained negative at $0.08, and the company continues to forecast $30 million-$35 million of 2026 net cash use. The new $100 million ATM program improves financing flexibility but introduces meaningful potential dilution, supporting a neutral overall assessment.
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Q2 2026 revenue was $4.944 million, more than double the $2 million reported in Q2 2025 and above the approximately $2.38 million estimate.
Full-year 2026 revenue guidance increased from approximately $10 million to $15 million, a $5 million or roughly 50% increase.
Management indicated year-end 2026 cash and investments of $115 million-$120 million, compared with prior guidance of approximately $100 million.
Expected 2026 net cash use was projected at $30 million-$35 million, while anticipated equipment-financing proceeds were $10 million-$15 million.
The company reported diluted EPS of negative $0.08 for Q2 2026, versus negative $0.08 in Q2 2025 and negative $0.07 in Q1 2026.
Disclosure controls were deemed effective as of June 30, 2026, and management reported no changes in internal control that materially affected, or were reasonably likely to materially affect, reporting controls.
On August 11, 2026, Hyliion authorized a new at-the-market program permitting sales of up to $100 million of common stock, creating potential shareholder dilution and financing dependence.
The ATM agreement permits sales-agent commissions of up to 3.0% of aggregate gross proceeds, which would reduce net proceeds from any equity issuance.
The company’s expected 2026 net cash use remains $30 million-$35 million despite the improved outlook, indicating continued cash consumption and potential need for additional financing.
Full-year 2026 revenue guidance was raised from approximately $10 million to $15 million. Management also indicated expected 2026 net cash use of $30 million-$35 million, year-end cash and investments of $115 million-$120 million, and anticipated equipment-financing proceeds of $10 million-$15 million.
Hyliion's Q1 2026 results showed impressive revenue growth driven by increased R&D services, reaching $2.83 million, significantly surpassing the $1 million estimate. The company improved its EPS loss to $0.07 from a…
Hyliion has repositioned to commercialize its KARNO Power Module (initial 200 kW unit) and pursue larger Multi‑MW systems (2 MW+ target) and an 800 kW modular unit planned for delivery to the U.S. Navy in 2026. The…
Hyliion reported first quarter revenue of $489,000 (research and development services) and a net loss of $17.3 million (EPS $(0.10)). Gross margin was 2.5% but operating loss remained large at $19.7 million. The company…
Hyliion has pivoted from powertrain to commercializing its KARNO linear generator, emphasizing a 200 kW product today and a modular 2 MW system targeted for commercialization in 2026. The filing highlights new…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.